Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vascular Biogenics (VBLT) and Zogenix (ZGNX).
Vascular Biogenics (VBLT)
In a report released today, Geulah Livshits from Chardan Capital reiterated a Hold rating on Vascular Biogenics, with a price target of $3. The company’s shares opened today at $1.87.
Livshits wrote:
“We are cautious on extrapolating to the phase III OVAL trial. While the data presented suggest an immune response after VB-111 treatment in ovarian cancer in the patients analyzed, we are cautious on extrapolating from a small number of patients to draw conclusions for the broader trial. This is particularly the case given the phase III patient had received prior immunotherapy including ipilimumab and IL2, which could theoretically impact subsequent immune responses to treatment in a way that may differ from the broader trial population. We therefore await the interim efficacy readout from the phase III trial, anticipated in 4Q19.”
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Vascular Biogenics with a $3 average price target.
See today’s analyst top recommended stocks >>
Zogenix (ZGNX)
In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Zogenix, with a price target of $70. The company’s shares opened today at $53.03.
Byrnes observed:
“We note that Zogenix ended the December 31st period w/ cash and equivalents of $514MM.”
According to TipRanks.com, Byrnes is a 1-star analyst with an average return of -0.4% and a 29.6% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Adamas Pharmaceuticals, Flexion Therapeutics, and Heron Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zogenix with a $72 average price target, which is a 35.8% upside from current levels. In a report issued on March 12, Mizuho Securities also maintained a Buy rating on the stock with a $69 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
